<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03537937</url>
  </required_header>
  <id_info>
    <org_study_id>171272</org_study_id>
    <nct_id>NCT03537937</nct_id>
  </id_info>
  <brief_title>Preliminary Investigation of optimaL Oxygen Targets Trial</brief_title>
  <acronym>PILOT</acronym>
  <official_title>Preliminary Investigation of optimaL Oxygen Targets (PILOT) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mechanical ventilation of ICU patients universally involves titration of the fraction of
      inspired oxygen (FiO2) to maintain arterial oxygen saturation (SpO2). Despite decades of ICU
      practice, however, the optimal SpO2 target remains unknown. Current guidelines offer
      divergent recommendations as to the optimal SpO2 target. Therefore, we propose a
      2,250-patient cluster-randomized cluster-crossover trial comparing a lower SpO2 target (90%;
      range 88-92%), an intermediate SpO2 target (94%; range 92-96%), and a higher SpO2 target
      (98%; range 96-100%) with regard to the outcome of days alive and free of invasive mechanical
      ventilation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>In the PILOT trial, the entire study ICU will be assigned to a single SpO2 target (cluster-randomized) and the ICU will switch between lower, intermediate, and higher SpO2 targets every two months in a randomly generated sequence (cluster-crossover).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Observer bias will be minimized by use of objective endpoints collected in duplicate by [1] study personnel blinded to group assignment and [2] automated data extraction from the electronic health record.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilator-free days (VFDs) to study day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days alive and free from invasive mechanical ventilation between the final liberation from invasive mechanical ventilation before 28 days and study day 28. Patients who continue to receive invasive mechanical ventilation at day 28 or have died prior to day 28 will receive zero VFDs. For patients who return to invasive mechanical ventilation and are subsequently liberated from invasive mechanical ventilation prior to day 28, VFDs will be counted from final liberation from mechanical ventilation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>All-cause mortality prior to transfer out of the intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>All-cause mortality prior to discharge from the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor-free days</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days alive and free from vasopressor receipt between the final receipt of vasopressors before 28 days and study day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of vasopressor receipt</measure>
    <time_frame>28 days</time_frame>
    <description>Total duration (in days) from the first receipt of vasopressors after enrollment to the final receipt of vasopressors before 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy-free days</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days alive and free from renal replacement therapy between the final receipt of renal replacement therapy before 28 days and study day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit-free days</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days alive and free from intensive care unit admission after the final transfer out of the intensive care unit before 28 days to study day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit length of stay</measure>
    <time_frame>28 days</time_frame>
    <description>Total duration (in days) from enrollment to final transfer out of the intensive care unit before 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>28 days</time_frame>
    <description>Total duration (in days) from enrollment to discharge from the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Sequential Organ Failure Assessment (SOFA) Score</measure>
    <time_frame>28 days</time_frame>
    <description>The SOFA score is made of 6 variables, each representing an organ system. Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure) The worst physiological variables will be collected serially every 24 hours of a patient's ICU admission. The &quot;worst&quot; measurement will be defined as the measure that correlates to the highest number of points. The SOFA score ranges from 0 to 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma creatinine</measure>
    <time_frame>28 days</time_frame>
    <description>Daily plasma creatinine value (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma lactate</measure>
    <time_frame>28 days</time_frame>
    <description>Daily plasma lactate value (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute respiratory distress syndrome (ARDS)</measure>
    <time_frame>28 days</time_frame>
    <description>Presence of ARDS by Berlin Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Kidney Injury (AKI)</measure>
    <time_frame>28 days</time_frame>
    <description>Presence of Stage II or greater AKI by Kidney Disease: Improving Global Outcomes (KDIGO) criteria</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Atrial arrhythmia</measure>
    <time_frame>28 days</time_frame>
    <description>Documented atrial arrhythmia</description>
  </other_outcome>
  <other_outcome>
    <measure>Ventricular arrhythmia</measure>
    <time_frame>28 days</time_frame>
    <description>Documented ventricular arrhythmia</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac arrest</measure>
    <time_frame>28 days</time_frame>
    <description>Cardiac arrest requiring chest compressions</description>
  </other_outcome>
  <other_outcome>
    <measure>Pneumothorax</measure>
    <time_frame>28 days</time_frame>
    <description>Documented pneumothorax</description>
  </other_outcome>
  <other_outcome>
    <measure>Arterial Oxygen Saturation (SpO2)</measure>
    <time_frame>28 days</time_frame>
    <description>Continuous values for SpO2 between enrollment and 28 days</description>
  </other_outcome>
  <other_outcome>
    <measure>Arterial Oxygen Saturation (SaO2)</measure>
    <time_frame>28 days</time_frame>
    <description>Values for SaO2 obtained on arterial blood gas</description>
  </other_outcome>
  <other_outcome>
    <measure>Fraction of inspired oxygen (FiO2)</measure>
    <time_frame>28 days</time_frame>
    <description>Continuous values for FiO2 between enrollment and liberation from invasive mechanical ventilation</description>
  </other_outcome>
  <other_outcome>
    <measure>Partial pressure of oxygen (PaO2)</measure>
    <time_frame>28 days</time_frame>
    <description>Values for PaO2 obtained on arterial blood gas</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of SpO2 values outside of SpO2 target range</measure>
    <time_frame>28 days</time_frame>
    <description>Proportion of all measured SpO2 values that lie outside the assigned SpO2 target range</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypoxemia by SpO2</measure>
    <time_frame>28 days</time_frame>
    <description>SpO2 &lt; 88% with FiO2 &lt; 1.0</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypoxemia by PaO2</measure>
    <time_frame>28 days</time_frame>
    <description>PaO2 &lt; 55 mm Hg with FiO2 &lt; 1.0</description>
  </other_outcome>
  <other_outcome>
    <measure>Hyperoxemia by SpO2</measure>
    <time_frame>28 days</time_frame>
    <description>SpO2 &gt; 98% with FiO2 &gt; 0.21</description>
  </other_outcome>
  <other_outcome>
    <measure>Hyperoxemia by PaO2</measure>
    <time_frame>28 days</time_frame>
    <description>PaO2 &gt; 120 mm Hg with FiO2 &gt; 0.21</description>
  </other_outcome>
  <other_outcome>
    <measure>Prolonged hypoxemia</measure>
    <time_frame>28 days</time_frame>
    <description>Episodes of SpO2 ≤ 85% lasting &gt; 5 minutes</description>
  </other_outcome>
  <other_outcome>
    <measure>Tidal volume</measure>
    <time_frame>28 days</time_frame>
    <description>Exhaled tidal volume (mL) from enrollment until liberation from invasive mechanical ventilation</description>
  </other_outcome>
  <other_outcome>
    <measure>Positive end-expiratory pressure (PEEP)</measure>
    <time_frame>28 days</time_frame>
    <description>PEEP (cm H2O) from enrollment until liberation from invasive mechanical ventilation</description>
  </other_outcome>
  <other_outcome>
    <measure>Peak airway pressure</measure>
    <time_frame>28 days</time_frame>
    <description>Peak airway pressure (cm H2o) from enrollment until liberation from invasive mechanical ventilation</description>
  </other_outcome>
  <other_outcome>
    <measure>Net fluid balance</measure>
    <time_frame>28 days</time_frame>
    <description>Net fluid balance (mL)</description>
  </other_outcome>
  <other_outcome>
    <measure>Receipt of a mandatory ventilator mode</measure>
    <time_frame>28 days</time_frame>
    <description>Receipt of a mandatory mode of invasive mechanical ventilation from enrollment until liberation from invasive mechanical ventilation</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of arterial blood gasses</measure>
    <time_frame>28 days</time_frame>
    <description>Number of arterial blood gasses performed as a part of clinical care</description>
  </other_outcome>
  <other_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>28 days</time_frame>
    <description>Hemoglobin level (mg/dL)</description>
  </other_outcome>
  <other_outcome>
    <measure>Red cell transfusion</measure>
    <time_frame>28 days</time_frame>
    <description>Receipt of packed red blood cell transfusion</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">2250</enrollment>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Lower SpO2 Target</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 90% (range 88-92%).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate SpO2 Target</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 94% (range 92-96%).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher SpO2 Target</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 98% (range 96-100%).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lower SpO2 Target</intervention_name>
    <description>SpO2 target 90% (range 88-92%)</description>
    <arm_group_label>Lower SpO2 Target</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intermediate SpO2 Target</intervention_name>
    <description>SpO2 target 94% (range 92-96%)</description>
    <arm_group_label>Intermediate SpO2 Target</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Higher SpO2 Target</intervention_name>
    <description>SpO2 target 98% (range 96-100%)</description>
    <arm_group_label>Higher SpO2 Target</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Receiving mechanical ventilation through an endotracheal tube or tracheostomy

          3. Admitted to the study ICU or admission to the study ICU from the emergency department
             is planned

        Exclusion Criteria:

          1. Known pregnancy or beta hCG level greater than the laboratory upper limit of normal in
             a patient capable of becoming pregnant

          2. Known to be a prisoner
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew W Semler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew W Semler, MD</last_name>
    <phone>(615) 322-3412</phone>
    <email>matthew.w.semler@vanderbilt.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Todd W Rice, MD</last_name>
    <phone>(615) 322-3412</phone>
    <email>todd.w.rice@vanderbilt.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew W Semler, MD</last_name>
      <phone>615-322-3412</phone>
      <email>matthew.w.semler@vanderbilt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Todd W Rice, MD</last_name>
      <phone>(615) 322-3412</phone>
      <email>todd.w.rice@vanderbilt.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Matthew Semler</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The NIH's guidelines for data sharing will serve as the model for the approach we will follow for the proposed investigation;
http://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm
Even though the final dataset will be stripped of identifiers prior to release for sharing, the inherent link between the period in which the patient was admitted to the study ICU and group assignment in a cluster-crossover trial introduces a significant risk for deductive disclosure of subjects. Thus, we will make the data and associated documentation available to users only under a data sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

